Study of Human Soft-Tissue Sarcoma Xenografts for Drug Testing
Author Information
Author(s): E Boven, HM Pinedo, AH van Hattum, PG Scheffer, WHM Peters, CAM Erkelens, HMM Schlooper, CM Kuiper, J van Ark-Ottel, G Giaccone
Primary Institution: Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
Hypothesis
The study aims to characterize human soft-tissue sarcoma xenografts to understand their chemosensitivity to various anti-cancer agents.
Conclusion
The chemosensitivity of the STS xenografts reflects clinical response rates in phase II trials on the same compounds in adult STS patients.
Supporting Evidence
- Growth inhibition > 75% was measured for doxorubicin in 20% of the STS xenografts.
- 30% growth inhibition was observed for cyclophosphamide in the xenografts.
- 20% growth inhibition was noted for vincristine in the xenografts.
- Etoposide was not effective in the STS xenografts.
- Three out of ten STS xenografts showed detectable MDR1 mRNA.
Takeaway
Researchers grew tumors from patients in mice to see how well different cancer drugs worked, finding that some drugs worked better than others.
Methodology
Ten human soft-tissue sarcoma xenografts were established in nude mice and tested for sensitivity to five anti-cancer agents.
Limitations
The study does not account for all potential drug resistance mechanisms in soft-tissue sarcomas.
Participant Demographics
Nine xenografts originated from patients needing chemotherapy.
Want to read the original?
Access the complete publication on the publisher's website